Charlotte Roy

Charlotte Roy

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Children
Verified
Journal Article
Open access
PDF file
ABAlastair Baker
Alastair Baker
EFEsteban Frauca
Esteban Frauca
JTJuan Torres
Juan Torres
LBLuz Yadira Bravo-Gallego
Luz Yadira Bravo-Gallego
EFEmer Fitzpatrick
Emer Fitzpatrick
PVPaloma Jara Vega
Paloma Jara Vega
(1) Background: Post-transplant lymphoproliferative disease (PTLD) is a significant complication of solid organ transplantation (SOT). However, there is lack of consensus in PTLD management. Our aim was to establish a present benchmark for comparison between international centers and between various organ transplant systems and modalities; (2) Methods: A cross-sectional questionnaire of relevant PTLD practices in pediatric transplantation was sent to multidisciplinary teams from 17 European center members of ERN TransplantChild to evaluate the centers’ approach strategies for diagnosis and treatment and how current practices impact a cross-sectional series of PTLD cases; (3) Results: A total of 34 SOT programs from 13 European centers participated. The decision to start preemptive treatment and its guidance was based on both EBV viremia monitoring plus additional laboratory methods and clinical assessment (61%). Among treatment modalities the most common initial practice at diagnosis was to reduce the immunosuppression (61%). A total of 126 PTLD cases were reported during the period 2012–2016. According to their histopathological classification, monomorphic lesions were the most frequent (46%). Graft rejection after PTLD remission was 33%. Of the total cases diagnosed with PTLD, 88% survived; (4) Conclusions: There is still no consensus on prevention and treatment of PTLD, which implies the need to generate evidence. This might successively allow the development of clinical guidelines.

13 December 2022 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
AGApolline Gonsard
Apolline Gonsard
RARola AbouTaam
Rola AbouTaam
BPBlandine Prévost
Blandine Prévost
CRCharlotte Roy
Charlotte Roy
AHAlice Hadchouel
Alice Hadchouel
DDDavid Drummond
David Drummond

1 November 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
CRCharlotte Roy
Charlotte Roy
FPFrançois Parquin
François Parquin
JMJonathan Messika
Jonathan Messika
BVBoussaud Véronique
Boussaud Véronique
OBOlivier Brugière
Olivier Brugière
ARAntoine Roux
Antoine Roux

21 January 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
EBEmmanuelle Bardin
Emmanuelle Bardin
NHNicolas Hunzinger
Nicolas Hunzinger
ELElodie Lamy
Elodie Lamy
CRCamille Roquencourt
Camille Roquencourt
BZBingqing Zhou
Bingqing Zhou
ISIsabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus
The triple combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) translates into major respiratory improvements in adults; yet current clinical endpoints may prove insufficiently sensitive in young children. We hypothesised that ETI rapidly modifies the lungs' metabolism, resulting in changes in breath composition. Eleven children with CF were enrolled in a longitudinal pilot study at the paediatric Necker hospital. Breath was collected on sorbent tubes using a ReCIVA® device before, after one week and one month of ETI. Samples were analysed by 2D-gas chromatography-mass spectrometry (2D-GC-MS). A linear mixed-effect model, corrected for clinical confounding factors, identified exhaled metabolites differentially expressed throughout the visits. Correlations were calculated between these and clinical indicators. Breath collection was successful in all children from six years old. They presented a decreased sweat chloride and improved lung function as early as within one week of ETI. Breath composition gradually evolved over the visits. ETI induced significant modifications in the level of 12 breath metabolites. Amongst those, dimethyl sulphide and tetradecene changes correlated with improvements in forced expiratory volume in one second (FEV1) and forced expiratory flow (FEF25-75), whilst 3-methyldecane and 3-(chloromethyl)-heptane were predictive of changes in lung clearance index (LCI2.5). ETI impacts the breath profile from the first week of treatment. Not only could "breathomics" bring mechanistic insights into the metabolic impact of ETI, but it may also offer novel non-invasive options to monitor CF disease and predict therapeutic response.

18 February 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
PLPauline Labé
Pauline Labé
MHMaya Husain
Maya Husain
PPPerrine Parize
Perrine Parize
MGMarion Grimaud
Marion Grimaud
CRCharlotte Roy
Charlotte Roy
JTJulie Toubiana
Julie Toubiana
Background: Infections caused by drug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa, are emerging in pediatric hospitals. New ß-lactam/ß-lactamase inhibitor combinations exhibit activity against these pathogens; however, there is limited data regarding their use in pediatric populations. Objectives: The study aimed to describe the characteristics of ceftazidime-avibactam (CAZ/AVI) and ceftolozane-tazobactam (C/T) prescriptions in children and assess their appropriateness. Methods: We retrospectively analyzed all CAZ/AVI or C/T prescriptions in children hospitalized in a French tertiary hospital between 2017 and 2022. All clinical, biological, and pharmacological data were collected prospectively as part of the antibiotic monitoring program set up by our antimicrobial stewardship (AMS) team. Results: In total, 50 CAZ/AVI and 25 C/T prescriptions were recorded, which concerned 21 and 20 patients, respectively. All patients had an underlying chronic condition. Most prescriptions originated from Pediatric Intensive Care Units and the Department of Pediatric Pulmonology and were mainly initiated for respiratory tract infections (n = 41/50, 82% of the CAZ/AVI prescriptions and n = 14/25, 56% of the C/T prescriptions). P. aeruginosa was the primary pathogen in documented infections for both CAZ/AVI and C/T prescriptions (n = 26/48, 54% and n = 16/19, 84%, respectively). Almost all prescriptions of CAZ/AVI and C/T were considered appropriate (n = 47/50, 94% for CAZ/AVI and n = 23/25, 92% for C/T, respectively) by the AMS team. Both CAZ/AVI and C/T treatments were well tolerated and resulted in clinical success in 33 (66%) and 19 (76%) cases, respectively. Conclusion: Our study suggests that CAZ/AVI and C/T are reasonable treatment options for children infected with Gram-negative pathogens resistant to carbapenems.

25 December 2025 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
SSSophie Schmartz
Sophie Schmartz
PCPierrick Cros
Pierrick Cros
CCCamille Cisterne
Camille Cisterne
ACAnia Carsin
Ania Carsin
TPThomas Perrin
Thomas Perrin
DDDavid Drummond
David Drummond
While treatment burden significantly impacts the management of pediatric asthma, no specific instrument exists to measure it in this population. To develop and validate a questionnaire measuring treatment burden in pediatric asthma from both children's and parents' perspectives. We conducted semi-structured interviews with 20 children (aged 8-12 years) with asthma and their parents to identify relevant components of treatment burden. Items were refined through a Delphi process with pediatric pulmonologists. The questionnaire was then validated in 202 parent-child dyads across eight teaching hospitals. Psychometric properties, including factorial validity, internal consistency, construct validity, and test-retest reliability, were assessed. The final questionnaire comprised 7 items for children (Cronbach's α=0.78) and 13 items for parents (Cronbach's α=0.86). Both versions demonstrated strong construct validity, with significant correlations with quality of life measures (rs=-0.52 for children, rs=-0.53 for parents) and global impression of treatment burden (r=+0.66 for children, r=+0.77 for parents). Test-retest reliability was acceptable for both children (ICC=0.72) and parents (ICC=0.80). Higher treatment burden scores were associated with being female (both for children and caregivers), having multiple scheduled visits, and poor asthma control. Parent and child scores showed moderate correlation (rs=0.33, P<.01), highlighting the importance of capturing both perspectives. This validated questionnaire provides a reliable tool for measuring treatment burden in pediatric asthma, enabling clinicians to better understand and address the impact of asthma management on children and their families.